Skip to main content

VOLITIONRX LTD

For the period ended Mar 31, 2024. Filed May 13, 2024.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2024 · Filed May 13, 2024

VNRX$0.18-7.8%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Condensed Consolidated Statements of Operations and Comprehensive Loss

Condensed Consolidated Statements of Operationsand Comprehensive Loss (Unaudited)

Three Months EndedMarch 31,
20242023
$$
Revenues
Service39,7765,356
Product131,759144,452
Total Revenues171,535149,808
Operating Expenses
Research and development4,629,5274,905,678
General and administrative2,253,7432,581,703
Sales and marketing1,672,7691,707,457
Total Operating Expenses8,556,0399,194,838
Operating Loss(8,384,504)(9,045,030)
Other Income (Expenses)
Grant income-165,795
Interest income8,65457,648
Interest expense(77,233)(51,322)
Loss on change in fair value of warrant liability(18,922)-
Total Other Income (Expenses)(87,501)172,121
Net Loss(8,472,005)(8,872,909)
Net Loss attributable to Non-Controlling Interest104,61793,361
Net Loss attributable to VolitionRx Stockholders(8,367,388)(8,779,548)
Other Comprehensive Income (Loss)
Foreign currency translation adjustments15,026(56,478)
Net Comprehensive Loss(8,456,979)(8,929,387)
Net Loss Per Share – Basic and Diluted attributable to VolitionRx Stockholders(0.10)(0.15)
Weighted Average Shares Outstanding – Basic and Diluted81,956,66060,176,975
(The accompanying notes are an integral part of these condensed consolidated financial statements)
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.